This study focuses on individuals with Cancer, specifically those with solid tumors that are either locally advanced, meaning they have grown into nearby tissues, or metastatic, which means the cancer has spread to other parts of the body. The investigation aims to evaluate the safety and effectiveness of an experimental medication called KD033, also known as SAR445710. This medication is administered as a solution for injection directly into a vein, a process known as intravenous administration.

The purpose of this study is to determine how much of the drug can be safely given and to observe how the body processes it. During the first part of the study, different groups of participants will receive increasing amounts of KD033 to find the maximum dose that can be tolerated without causing severe side effects. This involves monitoring for dose limiting toxicities, which are harmful side effects that prevent further increases in the amount of medicine given. The study also looks at pharmacokinetics, which describes how the drug moves through the body, and pharmacodynamics, which refers to the drug’s effects on the body.

Following the initial dose adjustments, an expansion phase will occur to further observe the safety and early signs of how well the medication works. Throughout the process, researchers will monitor adverse events, which are any unexpected or unpleasant medical occurrences that happen during the treatment. The study also tracks the best overall response to see if the tumors shrink or stabilize in size after receiving the medication.